Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile Unknown unknown
Therapy CRLX101 + Paclitaxel
Indication/Tumor Type fallopian tube cancer
Response Type not applicable


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown fallopian tube cancer not applicable CRLX101 + Paclitaxel Phase Ib/II Actionable In a Phase Ib/II trial, CRLX101 in combination with weekly Taxol (paclitaxel) resulted in an objective response rate (ORR) of 31.6% (6/19, 1 complete response, 5 partial responses) and a median progression-free survival of 5.4 months in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer, although the ORR was not superior to that of historical control (PMID: 33390325; NCT02389985). 33390325
PubMed Id Reference Title Details
(33390325) A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Full reference...